FeesSafety
Pluang+

Spectrum Business launches managed Secure Networking with Cisco 8000 Series to combat AI-driven security threats

Others
04 Nov 2026, 18:00 WIB
PRNewsWire
View Source
Bullish
Spectrum Business launches managed Secure Networking with Cisco 8000 Series to combat AI-driven security threats

Spectrum Business has introduced a new Managed Cisco Secure Networking solution featuring Cisco's 8000 Series Secure Routers and Talos Threat Intelligence. This service helps enterprises scale network capacity, enhance routing flexibility, and strengthen security against AI-enabled threats. Offered as a monthly subscription, it includes hardware, software, installation, and 24/7 expert support, allowing IT teams to focus on strategic tasks. This solution is among the first in North America to combine high-performance routing with post-quantum cryptography readiness for next-generation security needs.

Spectrum Business's new secure networking solution is presented here alongside Technology-sector market data from Pluang as of Nov 04, 2026 22:42 WIB. Among 150 priced US Technology stocks, 88 rose and 62 fell today. Notable movers include VNET with a 20.13% gain at USD 3.58 and a typical hold time of 18 days, CIFR down 18.35% at USD 6.63 with a 51% sell order activity, and XYZ up 15.66% at USD 87.87 with a 100% sell order activity and a typical hold time of 78 days.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
51 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
51 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
51 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
51 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
51 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App